{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T07:46:17Z","timestamp":1785743177615,"version":"3.56.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BJC Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Collision tumours, defined by the coexistence of two histologically distinct neoplasms within a single organ, are rare and typically arise from different cell lineages. We report a unique case of a 64-year-old woman with a history of oestrogen receptor (ER)\u2013positive, HER2-negative breast carcinoma who developed a renal mass later identified as a collision tumour comprising clear cell renal cell carcinoma (ccRCC) and metastatic breast carcinoma. Initial imaging and biopsy suggested ccRCC alone; however, post-nephrectomy histopathology revealed metastatic breast carcinoma foci within the ccRCC and renal sinus fat, confirmed by ER, GATA3, and mammaglobin positivity. This case highlights diagnostic challenges in distinguishing synchronous primaries from metastases, particularly where biopsy sampling may obscure dual pathology. Management required balancing treatment of localised ccRCC with systemic therapy for metastatic breast cancer. Multidisciplinary evaluation is essential to guide optimal care.<\/jats:p>","DOI":"10.1038\/s44276-026-00233-x","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T07:10:43Z","timestamp":1785741043000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic challenges of a renal collision tumour comprising clear cell renal cell carcinoma and metastatic breast carcinoma: a case report"],"prefix":"10.1038","volume":"4","author":[{"given":"AJP","family":"Fulton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AY","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Appukutty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Matakidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Ince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"O\u2019Carrigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Fife","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Eisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Shakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GD","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"McAdam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JO","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"233_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.humpath.2024.02.005","volume":"145","author":"LA Lerma","year":"2024","unstructured":"Lerma LA, Pease G, Malleis J, Antic T, Hes O, Tretiakova M. Actual encounters of the kidney kind: Exploring 48 cases of renal collision tumors through the lens of literature. Hum Pathol. 2024;145:26\u201333. https:\/\/doi.org\/10.1016\/j.humpath.2024.02.005.","journal-title":"Hum Pathol"},{"key":"233_CR2","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","volume":"386","author":"GN Hortobagyi","year":"2022","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386:942\u201350. https:\/\/doi.org\/10.1056\/NEJMoa2114663.","journal-title":"N Engl J Med"},{"key":"233_CR3","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.prp.2013.06.011","volume":"209","author":"M Amin","year":"2013","unstructured":"Amin M, Radkay L, Pantanowitz L, Fine J, Parwani A. Tumor-to-tumor metastasis (TTM) of breast carcinoma within a solitary renal angiomyolipoma: a case report. Pathol Res Pr. 2013;209:605\u20138. https:\/\/doi.org\/10.1016\/j.prp.2013.06.011.","journal-title":"Pathol Res Pr"},{"key":"233_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000172","volume":"2","author":"A Vogt","year":"2017","unstructured":"Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Cerny T, et al. Multiple primary tumours: challenges and approaches, a review. ESMO Open. 2017;2:e000172. https:\/\/doi.org\/10.1136\/esmoopen-2017-000172.","journal-title":"ESMO Open"},{"key":"233_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-022-01063-y","volume":"22","author":"V Belle Mbou","year":"2022","unstructured":"Belle Mbou V, Sanglier F, Pestre-Munier J, Descazeaud A, Labrousse F. Renal collision tumours: three additional case reports. BMC Urol. 2022;22:113. https:\/\/doi.org\/10.1186\/s12894-022-01063-y.","journal-title":"BMC Urol"},{"key":"233_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/314158","volume":"2015","author":"A Michalinos","year":"2015","unstructured":"Michalinos A, Constantinidou A, Kontos M. Gastric collision tumors: an insight into their origin and clinical significance. Gastroenterol Res Pr. 2015;2015:314158. https:\/\/doi.org\/10.1155\/2015\/314158.","journal-title":"Gastroenterol Res Pr"},{"key":"233_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14236","volume":"33","author":"CA Bulte","year":"2020","unstructured":"Bulte CA, Hoegler KM, Khachemoune A. Collision tumors: A review of their types, pathogenesis, and diagnostic challenges. Dermatol Ther. 2020;33:e14236. https:\/\/doi.org\/10.1111\/dth.14236.","journal-title":"Dermatol Ther"},{"key":"233_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12964-023-01178-1","volume":"21","author":"D Zipinotti Dos Santos","year":"2023","unstructured":"Zipinotti Dos Santos D, de Souza JC, Pimenta TM, da Silva Martins B, Junior RSR, Butzene SMS, et al. The impact of lipid metabolism on breast cancer: a review about its role in tumorigenesis and immune escape. Cell Commun Signal CCS. 2023;21:161 https:\/\/doi.org\/10.1186\/s12964-023-01178-1.","journal-title":"Cell Commun Signal CCS"},{"key":"233_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1056\/NEJMc2406031","volume":"391","author":"N Chakiryan","year":"2024","unstructured":"Chakiryan N, Strother M. Adjuvant pembrolizumab in renal-cell carcinoma. N Engl J Med. 2024;391:185\u20136. https:\/\/doi.org\/10.1056\/NEJMc2406031.","journal-title":"N Engl J Med"},{"key":"233_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00482-2","volume":"8","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Kabos P, Beck JT, Jerusalem G, Wildiers H, Sevillano E, et al. Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: phase 1b study. NPJ Breast Cancer. 2022;8:118. https:\/\/doi.org\/10.1038\/s41523-022-00482-2.","journal-title":"NPJ Breast Cancer"},{"key":"233_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejca.2021.05.035","volume":"154","author":"Y Yuan","year":"2021","unstructured":"Yuan Y, Lee JS, Yost SE, Frankel PH, Ruel C, Egelston CA, et al. Phase I\/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer. Eur J Cancer Oxf Engl 1990. 2021;154:11\u201320. https:\/\/doi.org\/10.1016\/j.ejca.2021.05.035.","journal-title":"Eur J Cancer Oxf Engl 1990"}],"container-title":["BJC Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44276-026-00233-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-026-00233-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-026-00233-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T07:10:44Z","timestamp":1785741044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44276-026-00233-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["233"],"URL":"https:\/\/doi.org\/10.1038\/s44276-026-00233-x","relation":{},"ISSN":["2731-9377"],"issn-type":[{"value":"2731-9377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GDS has received educational grants from AstraZeneca; consultancy fees from Evinova and Qurin; travel expenses from MSD; he is Clinical lead (urology) National Kidney Cancer Audit and Topic Advisor for the NICE kidney cancer guideline. WJH holds advisory and research roles at AstraZeneca, MSD, GSK, J\u2009+\u2009J, Merck Serono, Recordati, Ipsen, Regeneron and Bayer. TE is a Roche employee and has shares in both Roche and AstraZeneca. AM is a GSK employee and has shares in GSK and AstraZeneca KF has advisory, consultancy or speaker fees from ESAI, Ipsen, Merck, Eusa, MSD, Kyowa Kirin, Regeneron and Sanofi and conference support from Ipsen, MSD and EUSA and Institutional research funding from Merck, Exelixis. AW is a member of National Kidney Cancer Audit Clinical Reference Group. KM receives consultancy fees from Pfizer, AstraZeneca, FORTREA and NOVARTIS. They have received international meeting sponsorship from Novartis, Roche and Pfizer.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Written informed consent for publication of clinical details and images was obtained from the patient. Ethical approval was waived in accordance with institutional policy for single-patient case reports. This report was prepared in compliance with the CARE guidelines, and the corresponding checklist is included as supplementary material.","order":2,"name":"Ethics","label":"Ethics approval and consent","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"38"}}